Oct 10 (Reuters) - Akero Therapeutics said on Tuesday its drug to treat a type of fatty liver disease showed improvement in patients in a mid-stage trial, but the data showed that the results were not statistically significant. (Reporting by Leroy Leo in Bengaluru)
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
These proven wealth builders could be exactly what you're searching for right now.
Here's what could happen next to Microsoft shares.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
It's been an "everything buy bonds" bull rally in markets for months, but BofA is cautiously watching a couple of indicators.
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.
Put your money to work by investing in these three high-quality dividend stocks.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
Baron, whose largest position is in Tesla, is betting the new shift in strategy for Tesla’s low-cost car will fill its increasingly empty factories.